Transcutaneous Oxygen Tension and Bradykinin Concentration During Rheocarna Therapy: Case Series.

Introduction: Rheocarna therapy is believed to improve circulation via vasodilation; however, few reports have evaluated peripheral circulation during treatment.

Methods: Bradykinin plasma concentration, blood pressure (BP), and transcutaneous oxygen pressure (TcPO) were measured in two patients with chronic limb-threatening ischemia during Rheocarna therapy.

Results: Case 1 (wound grade 1) exhibited stable, high TcPO and no ulcer progression after 6 months.

Effectiveness and safety of plasma exchange for anti-MDA5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: A case series.

Introduction: Clinically amyopathic dermatomyositis (CADM) with anti-melanoma differentiation-associated gene 5 (MDA5) antibody (Ab) with rapidly progressive interstitial lung disease (RP-ILD) is often refractory for intensive immunosuppression. In this study, we verified the effectiveness and safety of plasma exchange (PEx) for this lethal disease.

Methods: We retrospectively examined the clinical course and adverse effect (AE) of 12 patients with anti-MDA5 Ab-positive CADM between January 2017 and December 2021 in our hospital.

Correlation between bradykinin concentration and blood pressure during Rheocarna therapy: A single-center case series.

Introduction: A novel LDL (low-density lipoprotein) apheresis therapeutic option, Rheocarna, has garnered attention as an alternative therapy for chronic limb-threating ischemia (CLTI). Bradykinin-mediated vasodilation is involved in the effects of LDL apheresis and a decrease in blood pressure (BP), but the changes in bradykinin concentration during Rheocarna therapy are unknown.

Methods: The study involved patients with CLTI treated with Rheocarna at our hospital, from April 2022 to August 2023.